

Understanding Health-Related Quality of Life among Lung Cancer Patients in India: Challenges and Opportunities.

Nootan Ramling Mali, Research Scholar, Malwanchal University, Indore

Dr. Berlin Sara Thampy, Research Supervisor, Malwanchal University, Indore

Introduction:

Lung cancer stands as a significant public health challenge globally, with its burden particularly pronounced in India. Health-related quality of life (HRQoL) is a crucial aspect of lung cancer management, reflecting the impact of the disease and its treatment on various domains of patients' lives. In India, where the healthcare landscape is diverse and resources are often limited, understanding the HRQoL among lung cancer patients is paramount for improving care and addressing the unique challenges they face.

Understanding Health-Related Quality of Life:

Health-related quality of life encompasses physical, psychological, social, and functional aspects of an individual's well-being in the context of their health status and healthcare interventions. For lung cancer patients, HRQoL is profoundly influenced by disease-related symptoms, treatment side effects, psychological distress, social support, and financial constraints.

Challenges Faced by Lung Cancer Patients in India:

1. **Late Diagnosis:** Lung cancer in India is often diagnosed at advanced stages, leading to poorer outcomes and increased symptom burden, which significantly affects HRQoL.
2. **Limited Access to Healthcare:** Disparities in healthcare access and infrastructure across different regions of India result in unequal access to timely diagnosis, treatment, and supportive care services for lung cancer patients.
3. **Stigma and Psychosocial Impact:** Lung cancer is associated with stigma and misconceptions, leading to social isolation, psychological distress, and diminished HRQoL among patients and their families.
4. **Financial Strain:** The high cost of lung cancer treatment, coupled with limited health insurance coverage and out-of-pocket expenditures, imposes a substantial financial burden on patients, affecting their HRQoL and treatment adherence.

Factors Influencing Health-Related Quality of Life:

1. **Symptom Burden:** Common symptoms of lung cancer, such as dyspnea, cough, fatigue, and pain, significantly impact patients' physical functioning and overall HRQoL.
2. **Treatment Side Effects:** Chemotherapy, radiation therapy, and surgery for lung cancer can lead to debilitating side effects, including nausea, vomiting, hair loss, and fatigue, which adversely affect patients' HRQoL.
3. **Psychological Distress:** Anxiety, depression, and existential concerns are prevalent among lung cancer patients in India, contributing to diminished HRQoL and affecting treatment compliance and decision-making.
4. **Social Support:** Adequate social support from family, friends, and healthcare providers plays a crucial role in enhancing coping mechanisms, resilience, and HRQoL among lung cancer patients.
5. **Palliative Care:** Integrating palliative care early in the management of lung cancer improves symptom control, enhances communication, and optimizes HRQoL for patients and their families.

Improving Health-Related Quality of Life for Lung Cancer Patients:

1. **Early Detection and Diagnosis:** Implementing lung cancer screening programs and raising awareness about early symptoms can facilitate timely diagnosis and intervention, improving patients' HRQoL.
2. **Multidisciplinary Care:** Adopting a multidisciplinary approach involving oncologists, pulmonologists, surgeons, palliative care specialists, and psychosocial support teams ensures comprehensive care addressing the diverse needs of lung cancer patients.
3. **Supportive Care Services:** Access to supportive care services, including symptom management, psychosocial support, nutritional counseling, and rehabilitation programs, is essential for optimizing HRQoL throughout the lung cancer continuum.
4. **Education and Counseling:** Providing patients and caregivers with information about the disease, treatment options, symptom management strategies, and psychosocial support resources empowers them to make informed decisions and cope effectively with the challenges of lung cancer.
5. **Policy and Advocacy:** Advocating for policies that promote equitable access to quality healthcare, including affordable cancer treatment, health insurance coverage, and

palliative care services, is critical for addressing the socio-economic determinants of HRQoL among lung cancer patients in India.

Conclusion:

Health-related quality of life is a multidimensional construct influenced by various clinical, psychological, social, and environmental factors among lung cancer patients in India. Addressing the challenges and optimizing HRQoL requires a holistic approach encompassing early detection, multidisciplinary care, supportive services, patient education, and policy advocacy. By prioritizing patient-centered care and fostering collaboration among stakeholders, India can enhance the well-being and outcomes of individuals living with lung cancer, ultimately improving the quality of life for patients and their families across the country.

Reference

1. Kumar S, Saikia J, Kumar V Jr, Malik PS, Madan K, Jain D, Bharati S. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario. *Curr Probl Cancer*. 2020;44(3):100563. doi: 10.1016/j.currproblcancer.2020.100563.
2. Wang Q, Wang P, Zhang L, Tessema M, Bai L, Xu X, Li Q. et al. Epigenetic regulation of RIP3 suppresses necroptosis and increases resistance to chemotherapy in nonsmall cell lung cancer. *Transl Oncol*. 2020;13(2):372–382. doi: 10.1016/j.tranon.2019.11.011.
3. Judd J, Borghaei H. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer. *Thorac Surg Clin*. 2020;30(2):199–206. doi: 10.1016/j.thorsurg.2020.01.006.
4. Kim R, Keam B, Hahn S, Ock CY, Kim M, Kim TM, Kim DW. et al. First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: a systematic review and network meta-analysis. *Clin Lung Cancer*. 2019;20(5):331–338. doi: 10.1016/j.clc.2019.05.009. e334. [
5. Rittberg R, Green S, Aquin T, Bucher O, Banerji S, Dawe DE. Effect of hospitalization during first chemotherapy and performance status on small-cell lung cancer outcomes. *Clin Lung Cancer*. 2020;21(5):e388–e404. doi: 10.1016/j.clc.2020.02.013

6. Akin S, Can G, Aydiner A, Ozdilli K, Durna Z. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. *Eur J Oncol Nurs*. 2010;14(5):400–409. doi: 10.1016/j.ejon.2010.01.003.
7. Gralla RJ, Thatcher N. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. *Lung Cancer*. 2004;46(Suppl 2):S41–47. doi: 10.1016/S0169-5002(04)80040-0.
8. Wintner LM, Giesinger JM, Zabernigg A, Sztankay M, Meraner V, Pall G, Hilbe W. et al. Quality of life during chemotherapy in lung cancer patients: results across different treatment lines. *Br J Cancer*. 2013;109(9):2301–2308. doi: 10.1038/bjc.2013.585.
9. Gu W, Xu YM, Zhu JH, Zhong BL. Depression and its impact on health-related quality of life among Chinese inpatients with lung cancer. *Oncotarget*. 2017;8(62):104806–104812. doi: 10.18632/oncotarget.21001.
10. Fischer IC, Cripe LD, Rand KL. Predicting symptoms of anxiety and depression in patients living with advanced cancer: the differential roles of hope and optimism. *Support Care Cancer*. 2018;26(10):3471–3477. doi: 10.1007/s00520-018-4215-0.
11. Yin S, Njai R, Barker L, Siegel PZ, Liao Y. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. *Popul Health Metr*. 2016;14(22) doi: 10.1186/s12963-016-0091-3.
12. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. *JAMA*. 1995;273(1):59–65. doi: 10.1001/jama.1995.03520250075037. [
13. Billis E, Koutsojannis C, Matzaroglou C, Gliatis J, Fousekis K, Gioftsos G, Papandreou M. et al. Association of low back pain on physical, sociodemographic and lifestyle factors across a general population sample within Greece. *J Back Musculoskelet Rehabil*. 2017;30(2):279–290. doi: 10.3233/BMR-150484.
14. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT. et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. *Lung Cancer*. 2013;81(2):280–287. doi: 10.1016/j.lungcan.2013.03.004.

15. Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, Orsini L. et al. Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the checkmate 017 study. *J Thorac Oncol.* 2018;13(2):194–204. doi: 10.1016/j.jtho.2017.10.029.
16. Togas C, George A, Fotios A. Evaluation of health-related quality of life in lung cancer patients in Greece and associations with demographic and medical characteristics. *Journal of Biosciences and Medicines.* 2019;7(10):17–31. doi: 10.4236/jbm.2019.710002.